Insulin-like growth factor 1 predicts decompensation and long-term prognosis in patients with compensated cirrhosis

Aim Insulin-like growth factor 1 (IGF-1), which is primarily produced in hepatocytes and associated with liver functional reserve, plays a crucial role the pathological condition of cirrhosis. This study aimed to investigate usefulness serum IGF-1 levels for predicting long-term prognosis decompensation development patients Methods We retrospectively evaluated 148 cirrhosis divided them into three groups according baseline levels: low (L)-, intermediate (I)-, high (H)-IGF-1 groups. The cumulative survival rates were compared among these compensated decompensated cirrhosis, respectively. Significant independent factors mortality identified using Cox proportional hazards regression analysis. Results median observation period was 57.1 (41.7–63.2) months. Thirty (20.3%) died disease-related events 21 (22.3%) developed decompensation. Multivariate analysis as significant (all patients: hazard ratio [HR], 0.967; p = 0.004; cirrhosis: HR, 0.927; 0.002). significantly lower L-IGF-1 group than H-IGF-1 I-IGF-1 < 0.001 0.009; 0.012 0.003, respectively). However, demonstrated no differences incidence higher ( 0.009, Low independently (HR, 0.939; 0.001). Conclusion poor Therefore, may be useful decompensation-related should regularly monitored management phase.